【摘要】 目的观察缬沙坦对高血压病患者血清过氧化物酶体增生物激活受体-γ(PPAR-γ)、血红素氧合酶-1(HO-1)水平的影响及其肾脏保护作用关系。方法将35～65岁高血压病患者60例随机分为缬沙坦组(80～160 mg/d)30例和常规治疗组30例,接受16周的治疗。治疗期间监测血压,分别于治疗前和治疗16周后采用Elisa方法检测血清PPAR-γ、HO-1水平;并检测尿β2-微球蛋白和尿微量蛋白含量。结果缬沙坦治疗可显著降低高血压病患者血压水平(P<0.01),升高血清HO-1和PPAR-γ水平(P<0.01),降低尿β2-微球蛋白和尿微量蛋白含量(P<0.01)。结论缬沙坦在血压治疗达标的同时可显著降低尿蛋白,作用机制推测可能与其炎症调控作用有关。更多还原

【Abstract】 Objective To observe the influence of valsartan on serum peroxisome proliferator activated receptor-γ(PPAR-γ) and heme oxygenase-1(HO-1) levels in hypertension patients and the relations with renal protection of hypertension patient.Methods Sixty patients with hypertension were randomly divided into conventional therapy group(30 cases) and valsartan therapy group(30 cases),after 16 weeks medication,the blood levels of PPAR-γ and HO-1 were detected with euzymelinked immunosorbent assay,and urine β2-microglobulin and urine small protein were detected at the same time.Results The blood levels of PPAR-γ and HO-1 in hypertension patients were lower than in healthy people.After 16 weeks drug therapy,the levels of PPAR-γ and HO-1 were increased significantly in valsartan group than that in conventional therapy group(P<0.01);urine β2-microglobulin and urine small protein were decreased after valsartan therapy(P<0.01).Conclusion Valsartan therapy can increase the levels of PPAR-γ and HO-1 in hypertension patients,at the same time,it can decrease urine β2-microglobulin and urine small protein.So we presumed that the renal function protection effect of valsartan in hypertension patients may due to its regulating on the expression of inflammation factors.更多还原